Results 51 to 60 of about 209,258 (305)
The Bumpy Road towards mTOR Inhibition in Glioblastoma: Quo Vadis?
Biomedicines, 2021 Glioblastoma multiforme (GBM), a grade IV astrocytoma, is a lethal brain tumor with a poor prognosis. Despite recent advances in the molecular biology of GBM, neuro-oncologists have very limited treatment options available to improve the survival of GBM ...
Kostas A. Papavassiliou +1 more
doaj +1 more source
mTORC2 signaling drives the development and progression of pancreatic cancer [PDF]
, 2016 mTOR signaling controls several critical cellular functions and is deregulated in many cancers, including pancreatic cancer. To date, most efforts have focused on inhibiting the mTORC1 complex.
Bardeesy, Nabeel +17 more
core +1 more source
Mammalian target of rapamycin inhibitors: A paradigm shift in current immunosuppression protocols
Indian Journal of Transplantation, 2016 Immunosuppression is an obligate necessity in kidney transplant. However, the standard immunosuppression causes chronic deterioration of allograft function over long term use. Mammalian target of rapamycin (mTOR) inhibitors provide an alternative in such
Indranil Ghosh, Manish Rathi
doaj +1 more source
Cellular effects of everolimus and sirolimus on podocytes. [PDF]
PLoS ONE, 2013 Everolimus (EVL) and Sirolimus (SRL) are potent immunosuppressant agents belonging to the group of mammalian target of rapamycin (mTOR) inhibitors used to prevent transplant rejection.
Sandra Müller-Krebs +6 more
doaj +1 more source
Role of mTOR signaling in tumor microenvironment. An overview [PDF]
, 2018 The mammalian target of rapamycin (mTOR) pathway regulates major processes by integrating a variety of exogenous cues, including diverse environmental inputs in the tumor microenvironment (TME).
Bazzichetto, Chiara +8 more
core +2 more sources
Targeting translation initiation by synthetic rocaglates for treating MYC-driven lymphomas. [PDF]
, 2020 MYC-driven lymphomas, especially those with concurrent MYC and BCL2 dysregulation, are currently a challenge in clinical practice due to rapid disease progression, resistance to standard chemotherapy, and high risk of refractory disease.
Bi, Chengfeng +15 more
core +1 more source
FEBS Letters, EarlyView.Fluorescent probes allow dynamic visualization of phosphoinositides in living cells (left), whereas mass spectrometry provides high‐sensitivity, isomer‐resolved quantitation (right). Their synergistic use captures complementary aspects of lipid signaling. This review illustrates how these approaches reveal the spatiotemporal regulation and quantitative
Hiroaki Kajiho +3 more
wiley +1 more source
A Phase I Study of Abiraterone Acetate Combined with BEZ235, a Dual PI3K/mTOR Inhibitor, in Metastatic Castration Resistant Prostate Cancer. [PDF]
, 2017 Lessons learnedThe combination of standard dose abiraterone acetate and BEZ235, a pan-class I PI3K and mTORC1/2 inhibitor, was poorly tolerated in men with progressive mCRPC.Although the clinical development of BEZ235 has been discontinued in prostate ...
Friedlander, Terence +6 more
core +1 more source
Gerosuppression by pan-mTOR inhibitors
Aging, 2016 Rapamycin slows organismal aging and delays age-related diseases, extending lifespan in numerous species. In cells, rapamycin and other rapalogs such as everolimus suppress geroconversion from quiescence to senescence. Rapamycin inhibits some, but not all, activities of mTOR.
Leontieva, Olga V. +1 more
openaire +2 more sources
Hematopoietic (stem) cells—The elixir of life?
FEBS Letters, EarlyView.The aging of HSCs (hematopoietic stem cells) and the blood system leads to the decline of other organs. Rejuvenating aged HSCs improves the function of the blood system, slowing the aging of the heart, kidney, brain, and liver, and the occurrence of age‐related diseases.
Emilie L. Cerezo +4 more
wiley +1 more source